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Abstract
Background: Some IPF patients show a rapid progression of respiratory failure. Most patients are treated with
high-dose corticosteroids. However, no large clinical studies have investigated the prognosis or efficacy of combined
treatments including high-dose corticosteroids in IPF patients with a rapid progression of respiratory failure.
Methods: We enrolled IPF patients who received mechanical ventilation and high-dose corticosteroids between April
2010 and March 2013. Records were extracted from a Japanese nationwide inpatient database. We conducted a
retrospective epidemiologic and prognostic analysis.
Results: Two hundred nine patients receiving an average of 12.8 days of ventilatory support were enrolled. There were
138 (66 %) fatal cases; the median survival was 21 days. The short-term (within 30 days) and long-term (within 90 days)
survival rates were 44.6 and 24.6 %, respectively. The average monthly admission rate among the IPF patients with the
rapid progression of respiratory failure in the winter was significantly higher than that in spring (p = 0.018). Survival did
not differ to a statistically significant extent in the different geographic areas of Japan. Survivors were significantly younger
(p = 0.002) with higher rates of mild dyspnea on admission (p = 0.012), they more frequently underwent bronchoscopy
(p < 0.001), and received anticoagulants (p = 0.027), co-trimoxazole (p < 0.001) and macrolide (p = 0.02) more frequently
than non-survivors. A multivariate logistic analysis demonstrated that two factors were significantly associated with a poor
prognosis: >80 years of age (OR = 2.94, 95 % Cl 1.044–8.303; p = 0.041) and the intravenous administration of high-dose
cyclophosphamide (OR = 3.17, 95 % Cl 1.101–9.148; p = 0.033). Undergoing bronchoscopy during intubation (OR = 0.25,
95 % Cl 0.079–0.798; p= 0.019) and the administration of co-trimoxazole (OR = 0.28, 95 % Cl 0.132–0.607; p = 0.001) and
macrolides (OR = 0.37, 95 % Cl 0.155–0.867; p = 0.033) were significantly associated with a good prognosis. The dosage of
co-trimoxazole significantly correlated with survival.
Conclusions: Co-trimoxazole and macrolides may be a good addition to high-dose corticosteroids in the treatment of
IPF patients with a rapid progression of respiratory failure.
Keywords: Acute exacerbation of idiopathic pulmonary fibrosis, Mechanical ventilation, Corticosteroid, Co-trimoxazole,
Macrolide, Nationwide database, Acute respiratory failure
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive par-
enchymal lung disease with an estimated median sur-
vival of 3–5 years from the time of diagnosis [1, 2]. The
disease behavior in patients with IPF is usually diverse,
with some IPF patients showing the rapid progression of
respiratory failure [3, 4]. The mortality rate in IPF
patients with severe respiratory failure who require a
ventilator is around 90 % [5].
Most of the severe IPF patients who show rapid pro-
gression of respiratory failure receive high-dose cortico-
steroids [3, 6]. The 2011 international evidence-based
guideline indicates that it as weak positive recommenda-
tion [2] in patients with definite or suspected [7] acute
exacerbation of IPF (AE-IPF). Thus far, however, there
have been no large clinical data sets to investigate the
prognosis of patients with AE-IPF who receive ventilator
treatment and high-dose corticosteroids. In addition, pa-
tients with AE-IPF are pathologically heterogeneous [8],
and the appropriate treatment strategy for AE-IPF pa-
tients is not fully understood. Recent treatments for
patients with AE-IPF include new agents, such as throm-
bomodulin [9, 10] and new ventilator setting strategies
that aim to avoid valotrauma [11, 12]. Such treatments
show some promise in their potential to improve the
survival rate.
The aim of the present study was to evaluate the epi-
demiology and prognosis of IPF patients with severe
rapid progression of respiratory failure who required
ventilator support in Japan, using a large, contemporary,
and comprehensive Japanese clinical database, and to ex-
plore effective combined treatment options that include
the administration of high-dose corticosteroids.
Methods
Data source
We used the Japanese Diagnosis Procedure Combination
(DPC) database, a nationwide inpatient database, to col-
lect patient data. The details of the DPC inpatient data-
base have been described previously [13]. Briefly, the
DPC is a case-mix patient classification system which in-
cludes the clinical data and information on the date of
admission, the charges, and the quantity of medical care
items. The database is linked with a lump-sum per-diem
payment system. Data from hospitals including all 82
university hospitals in Japan are gathered and merged
into a standardized electronic format by the Japanese
Ministry of Health, Labour, and Welfare. The database
covers more than 1,500 acute care hospitals located
throughout Japan and about 50,000 hospital beds. It rep-
resents approximately 50 % of all of the acute care
hospitalizations during the same period in Japan. The
database includes the main diagnoses, comorbidities
present at admission and in-hospital complications as
defined in the International Classification of Diseases
and Related Health Problems, 10th Revision (ICD-10)
codes and text data (in Japanese). The database also in-
cludes the following data: patient age and sex; height;
body weight; Fletcher, Hugh-Jones (F, H-J) classification;
Brinkman Index; drug use; diagnostic and therapeutic
procedures; date of admission; length of stay; status at
discharge; and the unique identifiers of the hospitals. At-
tending physicians are obliged to record the diagnoses
for each patient at discharge with reference to medical
charts to optimize the accuracy of the recorded diagno-
ses. All of the data were anonymously collected in the
database, thus the requirements for informed consent
were waived. This study was approved by the Ethics
Committee of Tokyo Medical and Dental University,
Tokyo, Japan (approval number 788).
Patient selection and data retrieval
From the total of 39,504 patients who were admitted to
the hospitals with a principal diagnosis of other intersti-
tial pulmonary diseases with fibrosis (ICD-10 code J841)
and who were discharged between April 2010 and
March 2013 patients, we excluded 35,900 patients who
did not receive invasive mechanical ventilation within
one week after admission because we intended to only
evaluate IPF patients with the rapid progression of re-
spiratory failure. Next, non-IPF patients (n = 1,655) were
excluded based on the text data, followed by patients
who were not treated with high-dose corticosteroids
(methylprednisolone: ≥500 mg, daily) within one week
after admission (n = 1,740). The final study population
included 209 patients (Fig. 1). These patients did not in-
clude any patients with viral, fungal or infectious bacter-
ial pulmonary diseases as the main diagnosis or as
comorbidities at the time of admission.
Definition of variables
Subjective respiratory symptoms, such as cough and dys-
pnea, were measured using the F, H-J classification [14].
The institution criteria authorized by The Japanese Re-
spiratory Society were used for defining a respiratory
specialized hospital. The seasons on admission were de-
fined as follows: “spring,” from March to May; “sum-
mer,” from June to August; “fall,” from September to
November; and “winter” from December to February.
Statistical analyses
A poisson multivariable regression analysis was used to
evaluate the differences in the admission rates between
the seasons to adjust for the effect of the fiscal year. The
chi-squared test or Fisher's exact test were used as ap-
propriate to analyze the differences in the clinical fea-
tures between survivors and non-survivors. To analyze
the prognostic factors for overall survival, a univariate
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logistic regression were initially used to select statisti-
cally significant clinical characteristics (sex, age, per-
forming bronchoscopy and an F, H-J classification) and
to evaluate each treatment effect (the variables included
treatments were applicable at least 10 % of all patients).
The final multivariate logistic regression models with
backward elimination were also used including the pre-
dictors (sex, age, significant clinical characteristics and
the treatment). Odds ratios (OR) and 95 % confidence
intervals (CI) were calculated. P values of <0.05 were
considered to be statistically significant. All calculations
were performed using the STATA 13 software program
(Stata, College Station, TX).
Results
Patient characteristics
The clinical characteristics of the patients are shown in
Table 1. The mean (standard deviation; SD) age was
72.3 (9.6) years and 82.3 % of the patients were men.
The average monthly admission rate among the IPF pa-
tients with the rapid progression of respiratory failure
in the winter was significantly higher than that in
spring (p = 0.018), but was not significantly different to
the rates in summer (p = 0.065) and fall (p = 0.379). The
rate of emergent transfer was 48.3, and 82.8 % of the
patients were admitted to specialty hospitals. Ventila-
tory support was provided for an average of 12.8 days.
Outcome
The number of patients with fatal outcomes was 138
of 209 (66 %) during the observation period. The
median survival period was approximately 21 days
after admission. The short-term (within 30 days) and
long-term (within 90 days) survival rates were 44.6
and 24.6 %, respectively (Fig. 2). The Hokuriku area
had the highest rate of short-term survival (60 %),
however, this rate was not significantly different from
other areas (Fig. 3). Bronchoscopy and tracheostomy
was performed in 20 (9.6 %) and 16 (7.7 %) patients
during hospitalization, respectively. The patient char-
acteristics of the survivors (patients who discharged
alive) and the non-survivor (patients who died in the
hospital) are summarized in Table 2. The survivors were
younger (p = 0.002), with mild symptoms of dyspnea on
admission (p = 0.012), higher rates of bronchoscopy dur-
ing intubation (p < 0.001), anticoagulant (unfractionated
and low-molecular-weight heparin) use (p = 0.027), co-
trimoxazole use (p < 0.001) and macrolide use (p = 0.020)
in comparison to non-survivors. Twenty-seven of 71
(38 %) survivors who were discharged from the hospitals
received home oxygen therapy.
Prognostic factors
A univariate logistic analysis indicated two significant
risk factors for in-hospital mortality: ≥80 years of age
(p = 0.033) and an F, H-J classification scale of 5 (p =
0.012), whereas the performance bronchoscopy, and
the use of anticoagulants, co-trimoxazole and macro-
lides were correlated with a good prognosis (Table 3).
The multivariate logistic analysis demonstrated that
two variables were significantly correlated with in-
hospital mortality: ≥80 years of age (p = 0.041) and
Fig. 1 Sample Selection
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the intravenous administration of high-dose cyclo-
phosphamide (≥100 mg, daily) (p = 0.033). In contrast,
the following variables were significantly correlated
with a good prognosis: the performance of bronchos-
copy during intubation (OR = 0.25, 95 % Cl 0.079–0.798;
p = 0.019), and the administration of co-trimoxazole (OR
= 0.28, 95 % Cl 0.132–0.607; p = 0.001) and macrolides
(OR = 0.37, 95 % Cl 0.155–0.867; p = 0.022). The mortality
rates of the patients who were treated in specialty and
non-specialty hospitals did not differ to a statistically sig-
nificant extent.
The relationship between survival and co-trimoxazole
dosage
We examined the difference in the survival rates of pa-
tients who were treated with by co-trimoxazole tablets
(sulfamethoxazole [400 mg] and trimethoprim [80 mg])
or the equivalent dose of co-trimoxazole granules and
injections. Figure 4 represents the relationship between
the survival rates of three groups of patients who were
treated with different doses of co-trimoxazole. The doses
were defined as follows: high dose (solid line; ≥6 tablets
daily, n = 74), low dose (broken line; 1–5 tablets daily, n
= 41) and no co-trimoxazole (dotted line; n = 94). Co-
trimoxazole treatment in the low-dose and high-dose
groups was initiated an average of 7.9 and 8.3 days after
admission, respectively. The survival of the patients in
the high-dose group was significantly longer than that in
the low-dose and no co-trimoxazole groups (log rank p
< 0.001). The survival of the patients in the low-dose
group was also significantly longer than that in the no
co-trimoxazole group (log rank p = 0.009) (Fig. 4).
Discussion
Thus far, there have been no large data sets on the prog-
nosis and prognostic factors in IPF patients with rapid
progression of respiratory failure. The data of the
present study, which were extracted from a nation-wide
Japanese epidemiological database show, for the first
time, the current prognosis of IPF patients with rapid
progression of respiratory failure who receive treatment
with high-dose corticosteroids. Treatments with co-
trimoxazole and macrolides were significantly associated
Table 1 The clinical characteristics of the participants
N (%) Mean ± SD
Patients 209


























Yes/No 173 (82.8)/36 (17.2)
Arrival by ambulance
Yes/No 101 (48.3)/108 (51.7)
Abbreviations: BMI body mass index, F, H-J Fletcher, Hugh-Jones. Values are
given as mean ± SD or n (%). The total dose was not equal to 209 because there
were missing values in the data file. *Significantly different in comparison to
spring (p = 0.018, poisson regression)
Fig. 2 Kaplan-Meier estimates of survival from the time of admission
for all of the IPF patients
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with a good prognosis and are considered to be effective
when administered in combination with high-dose corti-
costeroids. The performance of bronchoscopy during
ventilatory support was also correlated with a good
prognosis. Conversely, the intravenous administration of
high-dose cyclophosphamide was significantly associated
with a poor prognosis. Our findings suggest that these
managements may improve the morbidities associated
with severe rapidly progressive of IPF.
Using a large, nationally representative Japanese data-
base allowed us to investigate the prognostic factors for
in-hospital mortality in IPF patients with rapid progres-
sion of respiratory failure. The application of mechanical
ventilation in IPF patients with respiratory failure is con-
sidered to be a “weak” recommendation [2]. The 90-day
mortality rate of patients with severe rapidly progressive
IPF who received mechanical ventilation (75.4 %) was
lower than the previously reported rate (approximately
90 %) [5, 15]. Our results indicate that in such patients,
the provision of mechanical ventilation may still be con-
troversial. Similarly to stable patients with IPF [16], IPF
patients who were older than 80 years of age showed a
very poor prognosis in the present study. According to
our data, ventilatory support may not be recommended
in these patients. Similar to a previous report [17], a sig-
nificantly higher number of patients were admitted due
to IPF with rapid progression of respiratory failure in
winter than in spring; however, there were no location-
based differences in Japan. In contrast with stable
patients with IPF [18], no differences of mortality were
observed according to whether or patients were admit-
ted to specialty or non-specialty hospitals.
Although there have only been limited data on the role
of bacterial infection in IPF patients, recent reports sug-
gest the high importance of infectious causes and the
importance of the progression of IPF [19, 20] in the de-
velopment of AE-IPF [21]. In cases where the exclusion
of infectious causes was insufficient (e.g. when they were
diagnosed by the analysis of endotracheal aspirate or
bronchoalveolar lavage fluid), they were considered as
cases of suspected AE-IPF. It has been reported that the
prognosis of patients with suspected AE-IPF is not
significantly different to that of patients with definite
AE-IPF [7]. The data in the present study showed that
the performance of bronchoscopy might be related to a
better prognosis (Table 3). The majority of AE-IPF pa-
tients received empiric antimicrobial treatments, which
targeted common respiratory pathogens (although there
has been no data to support their use in AE-IPF pa-
tients) [22]. The infectious causes of respiratory failure
can easily missed, even when several microbiological
tests are performed for clinical reasons: in the treatment
of such patients it is not usually possible to wait for
microbiological results, and antimicrobial treatments are
Fig. 3 The definition of the regions in Japan and short-term mortality
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considered to be low-risk. The results of the present
study suggest that antibiotic treatments (other than co-
trimoxazole and macrolides) may not contribute to the
survival of AE-IPF patients with respiratory failure. This
study also showed a trend towards poor survival in pa-
tients who were treated with immunosuppressants, espe-
cially intravenous high-dose cyclophosphamide. Currently,
there is no strong evidence to support the use of immuno-
suppressants in AE-IPF patients with respiratory failure,
and further studies will be needed to evaluate the role of
immunosuppressants when they are administered in com-
bination with high-dose corticosteroids.
Several reports have described the relationship between
the prognosis of IPF patients and the administration of
co-trimoxazole or macrolides. Shimizu et al. hypothesized
that the specific role of co-trimoxazole was linked to a
high prevalence of Pneumocystis jiroveci colonization
among patients with stable IPF [23]. Shulgina et al. also
reported that the addition of co-trimoxazole therapy to
the standard treatment for stable patients with fibrotic
idiopathic interstitial pneumonia resulted in improved
quality of life and a reduction in mortality [24]. Huie et al.
investigated the potential role of infection in the exacerba-
tion of acute respiratory symptoms in patients with IPF
[25] and showed P. jiroveci may be associated with the on-
set of AE-IPF. Our data indicated that the administration
of co-trimoxazole mortality in IPF patients with rapid pro-
gression of respiratory failure, not only at the treatment
Table 2 The comparison of the clinical features of survivors and the non-survivors
Survivors Non-survivors p-value
Patients 71 138
Age, years 69.3 ± 10.2 73.8 ± 8.8 0.002
Male 56 (78.9) 116 (84.1) 0.352
BMI, kg/m2 22.2 ± 3.9 22.3 ± 3.8 0.795
Brinkman Index
0/1–800/>800 26/14/25 42/31/46 0.719
F, H-J Classification scale
1/2/3/4/5 1/3/3/16/42 1/1/4/12/83 0.012
Specialty hospital care 60 (84.5) 113 (81.9) 0.634
Ambulance transfer 32 (45.1) 69 (50.0) 0.499
Performing bronchoscopy 14 (19.7) 6 (4.4) <0.001
Treatment regimen use
Sivelestat 37 (52.1) 67 (48.9) 0.626
Diuretic drug 37 (52.1) 65 (47.1) 0.492
Anticoagulant therapy 37 (52.1) 50 (36.2) 0.027
Immunosuppressive therapy 30 (42.3) 45 (32.6) 0.169
Intravenous high-dose cyclophosphamide 9 (12.7) 23 (16.7) 0.448
PMX 4 (5.6) 9 (6.5) 0.801
Recombinant human soluble thrombomodulin 3 (4.2) 6 (4.4) 0.967
Antibiotic therapy 71 (100) 135 (97.8) 0.211
β-Lactams 60 (84.5) 116 (84.1) 0.933
Co-trimoxazole 56 (78.9) 59 (42.8) <0.001
Quinolones 38 (53.5) 65 (47.1) 0.379
Macrolides 23 (32.4) 25 (18.1) 0.020
Tetracycline 6 (8.5) 12 (8.7) 0.952
Anti-MRSA antibiotics 6 (8.5) 11 (7.8) 0.904
Clindamycin 3 (4.2) 2 (1.5) 0.214
Aminoglycoside 2 (2.8) 1 (0.7) 0.228
Others 5 (7.0) 7 (5.1) 0.562
Data are presented as mean ± SD or n (%), unless otherwise indicated. Definition of abbreviations: BMI = Body Mass Index, F, H-J = Fletcher, Hugh-Jones, PMX = Direct
hemoperfusion with polymyxin B-immobilized fiber, MRSA =Methicillin-resistant Staphylococcus aureus. The total dose was not equal to 209 because there were missing
values in the data file
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dose for P. jiroveci but also at lower doses. This favorable
effect of co-trimoxazole might, in addition to its anti-
microbial activity against P. jiroveci, may be due to its anti-
inflammatory effect: co-trimoxazole might have reduced
the neutrophil-derived oxidative stress [26]. Macrolides
have also been reported to have anti-inflammatory effects
[27, 28]. Kawamura et al. reported that azithromycin was
associated with improved outcomes in patients with acute
exacerbation of chronic fibrosing interstitial pneumonia
[29]. The administration of macrolides and co-trimoxazol
Table 3 Prognostic factors for survival
Variable Univariate logistic analysis Multivariate logistic analysis
N (%) OR 95 % Cl p-value OR 95 % Cl p-value
Age, years 209
<60 17 (8.1) ref ref
60–69 52 (24.9) 1.12 0.374–3.362 0.839
70–79 98 (46.9) 1.83 0.647–5.196 0.254
≥80 42 (20.1) 3.78 1.110–12.858 0.033 2.94 1.044–8.303 0.041
Male 172 (82.3) 1.41 0.681–2.930 0.354
BMI, kg/m2 178
<18.5 27 (15.2) ref
18.5–25 114 (64.0) 1.43 0.604–3.388 0.415
>25 37 (20.8) 1.13 0.409–3.117 0.814
Brinkman Index 184
0 68 (37.0) ref
1–800 45 (24.5) 1.37 0.617–3.046 0.439
>800 71 (33.6) 1.14 0.571–2.271 0.712
F, H-J Classification scale 166
1–4 41 (24.7) ref ref
5 125 (75.3) 2.53 1.229–5.187 0.012 2.13 0.931–4.856 0.073
Specialty hospital care 173 (82.8) 0.83 0.382–1.799 0.635
Ambulance transfer 101 (48.3) 1.22 0.686–2.164
Performing bronchoscopy 20 (9.6) 0.19 0.068–0.506 0.001 0.25 0.079–0.798 0.019
Sivelestat 104 (49.8) 0.87 0.489–1.538 0.626
Diuretic drug 102 (48.8) 0.82 0.461–1.451 0.493
Anticoagulant therapy 87 (41.6) 0.52 0.292–0.933 0.028
Immunosuppressive therapy 75 (35.9) 0.66 0.366–1.193 0.17
Intravenous high-dose cyclophosphamide 32 (15.3) 1.38 0.601–3.160 0.449 3.17 1.101–9.148 0.033
PMX 13 (6.2) 1.17 0.347–3.935 0.801
Recombinant human soluble thrombomodulin 9 (4.3) 1.03 0.250–4.247 0.967
Antibiotic therapy 206 (98.6) – –
β-Lactams 176 (84.2) 0.97 0.440–2.126 0.933
Co-trimoxazole 115 (55.0) 0.20 0.103–0.388 <0.001 0.28 0.132–0.607
Quinolones 103 (49.3) 0.77 0.436–1.372 0.38
Macrolides 48 (23.0) 0.46 0.239–0.893 0.022 0.37 0.155–0.867
Tetracycline 18 (8.6) 1.03 0.370–2.875 0.952
Anti-MRSA antibiotics 17 (8.1) 0.94 0.332–2.651 0.904
Clindamycin 5 (2.4) 0.33 0.054–2.042 0.235
Aminoglycoside 3 (1.4) 0.25 0.022–2.826 0.264
Others 12 (5.7) 0.71 0.216–2.307 0.564
Data are presented as n (%), unless otherwise indicated. Definition of abbreviations: BMI body mass index, F, H-J Fletcher, Hugh-Jones, PMX Direct hemoperfusion
with polymyxin B-immobilized fiber, MRSA Methicillin-resistant Staphylococcus aureus
Oda et al. BMC Pulmonary Medicine  (2016) 16:91 Page 7 of 9
may therefore increase the survival rate in patients with
AE-IPF.
The present study is associated with several limita-
tions. First, this study was a retrospective observational
study. However, the analysis of the large data set of the
DPC database system allowed us to perform our study
in a large patient population. Tzilas et al. reported the
weakness of the ICD coding system [30]; however, in
addition to the ICD data our study also used the text
data that were recorded in the DPC database system to
clarify the physicians’ diagnoses. Second, several clinical
variables were not obtained, including the medication
data and the patients’ respiratory function before admis-
sion, and the results of bacteriological tests. However,
we only enrolled IPF patients with rapid progression of
respiratory failure in whom a ventilator was used on ad-
mission to ensure that the severity of IPF in our study
population was uniform at the start of the observation
period. Third, the DPC database system can only record
in-hospital data, thus the data of the patients who were
discharged from the DPC hospitals was not available
and the contribution of their medications to survival
may be underestimated. Finally, it is uncertain whether
the regional clinical pathway would work the same way
in other countries where health systems and policies dif-
fer from those in Japan. The effectiveness of the clinical
pathway has been shown to be inconsistent in different
areas and further studies are necessary to examine the
applicability of this system to other countries.
Conclusion
We herein showed the epidemiology and prognosis of IPF
patients with rapid progression of respiratory failure in re-
cent years using a national administrative database in Japan.
The performance of bronchoscopy during intubation, and
the administration of co-trimoxazole and macrolides were
significantly good prognostic factors. The concomitant use
of co-trimoxazole in addition to high-dose corticosteroids
may improve survival in IPF patients with rapid exacerba-
tion of respiratory failure. Further clinical trials are neces-
sary to verify the findings of the present study.
Key messages
 Rapid progression of respiratory failure in IPF
patients was frequently seen in the winter. Older age
and a higher grade of dyspnea on admission were
poor prognostic factors. In addition, the prognosis of
the patients did not differ in relation to the
geographic area of Japan or in patients who were
treated in a specialized hospital.
 The results of this study indicate that the prognosis
of patients who underwent a bronchoscopic
examination was better prognosis than those who
did not; however, the performance of bronchoscopy
in AE-IPF patients might be controversial.
 Regarding the treatment of IPF patients with
rapid progression of respiratory failure, the use of
high-dose corticosteroids in combination with
macrolides and co-trimoxazole may lead to a
better prognosis. However, prospective randomized
controlled trials are necessary to elucidate the clinical
effects of these agents.
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